Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics announced the dosing of the first patient in a Phase 1b/2a clinical trial evaluating CT2000, an investigational NaV1.7 inhibitor eye drop formulation, as a treatment for acute and chronic ocular pain associated with dry eye disease. The trial will assess safety and efficacy with results expected by the end of 2026. Positive pre…